Literature DB >> 24072607

Interleukin 6(-174G/C) variant and its circulating levels in coronary artery disease patients and their first degree relatives.

Rajesh Kumar Galimudi1, Mrudula K Spurthi, Chiranjeevi Padala, Kishore G Kumar, Saraswati Mudigonda, Srilatha G Reddy, Mohini T Aiyengar, Sanjib K Sahu, Surekha H Rani.   

Abstract

Interleukin-6 (IL-6) a pleiotropic cytokine is a central mediator of inflammation in the pathogenesis of coronary artery disease (CAD). Our aim is to evaluate the serum levels of IL-6 and C-reactive protein (CRP) and to analyze the IL-6 polymorphism in CAD patients and to identify the first-degree relatives (FDRs) at risk of the disease in comparison with healthy controls. Estimation of IL-6 levels by enzyme-linked immunosorbent assay (ELISA) and CRP by latex reagent kit method, and genotyping of IL6 gene variants -174 (G>C) was carried out by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 600 subjects. IL-6 and CRP levels were significantly high in patients followed by FDRs compared to controls. The frequency of the IL-6 genotype was significantly different between cases, FDRs and controls and association of serum IL-6 levels with genotype found to be significant in CC genotype compared to GC and GG at p < 0.01 in CAD patients and FDRs, while there is no significant difference observed in controls. The study shows the importance of inflammation in the pathogenesis of CAD and predicts the risk of future coronary events in healthy asymptomatic FDRs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24072607     DOI: 10.1007/s10753-013-9742-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  30 in total

1.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

Authors:  W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

2.  Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

Authors:  J M Fernandez-Real; M Vayreda; C Richart; C Gutierrez; M Broch; J Vendrell; W Ricart
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

3.  Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.

Authors:  C F Terry; V Loukaci; F R Green
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

4.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.

Authors:  S E Humphries; L A Luong; M S Ogg; E Hawe; G J Miller
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

5.  Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Témoin de l'Infarctus du Myocarde.

Authors:  J L Georges; V Loukaci; O Poirier; A Evans; G Luc; D Arveiler; J B Ruidavets; F Cambien; L Tiret
Journal:  J Mol Med (Berl)       Date:  2001-06       Impact factor: 4.599

6.  Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes.

Authors:  Matthias Möhlig; Heiner Boeing; Joachim Spranger; Martin Osterhoff; Anja Kroke; Eva Fisher; Manuela M Bergmann; Michael Ristow; Kurt Hoffmann; Andreas F H Pfeiffer
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

8.  Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases?

Authors:  Marie Bennermo; Claes Held; Sten Stemme; Carl-Göran Ericsson; Angela Silveira; Fiona Green; Per Tornvall
Journal:  Clin Chem       Date:  2004-09-13       Impact factor: 8.327

9.  Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor.

Authors:  Sven Wassmann; Michaela Stumpf; Kerstin Strehlow; Andreas Schmid; Bernhard Schieffer; Michael Böhm; Georg Nickenig
Journal:  Circ Res       Date:  2003-12-29       Impact factor: 17.367

10.  GATA2 is associated with familial early-onset coronary artery disease.

Authors:  Jessica J Connelly; Tianyuan Wang; Julie E Cox; Carol Haynes; Liyong Wang; Svati H Shah; David R Crosslin; A Brent Hale; Sarah Nelson; David C Crossman; Christopher B Granger; Jonathan L Haines; Christopher J H Jones; Jeffery M Vance; Pascal J Goldschmidt-Clermont; William E Kraus; Elizabeth R Hauser; Simon G Gregory
Journal:  PLoS Genet       Date:  2006-07-20       Impact factor: 5.917

View more
  12 in total

Review 1.  Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis.

Authors:  Haifeng Hou; Chenglin Wang; Fengjing Sun; Linlin Zhao; Aishe Dun; Zheng Sun
Journal:  Inflamm Res       Date:  2015-07-15       Impact factor: 4.575

2.  The Association of IL-6, TNFα and CRP Gene Polymorphisms with Coronary Artery Disease in a Tunisian Population: A Case-Control study.

Authors:  Nedra Grira; Dhaker Lahidheb; Oussama Lamine; Manel Ayoub; Souhir Wassaifi; Zied Aouni; Wafa Fehri; Chakib Mazigh
Journal:  Biochem Genet       Date:  2021-02-01       Impact factor: 1.890

3.  Dual Effect of IL-6 -174 G/C Polymorphism and Promoter Methylation in the Risk of Coronary Artery Disease Among South Indians.

Authors:  Bobbala Indumathi; Shiva Krishna Katkam; L S R Krishna; Vijay Kumar Kutala
Journal:  Indian J Clin Biochem       Date:  2018-02-21

4.  Quantile-Dependent Expressivity of Serum Interleukin-6 Concentrations as a Possible Explanation of Gene-Disease Interactions, Gene-Environment Interactions, and Pharmacogenetic Effects.

Authors:  Paul T Williams
Journal:  Inflammation       Date:  2022-01-07       Impact factor: 4.657

5.  Role of IL-6 -174(G/C) promoter polymorphism in the etiology of early-onset preeclampsia.

Authors:  Sabnavis Sowmya; Aruna Ramaiah; Pratibha Nallari; Akka Jyothy; Ananthapur Venkateshwari
Journal:  Inflamm Res       Date:  2015-04-28       Impact factor: 4.575

6.  Gene-gene interactions among CX3CL1, LEPR and IL-6 related to coronary artery disease in Chinese Han population.

Authors:  Song-Gen Jin; Guo-Lin Chen; Song-Liu Yang; Ming-Yan Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Association between IL-18/18R gene polymorphisms and coronary artery disease: influence of IL-18/18R genetic variants on cytokine expression.

Authors:  Vadim Mitrokhin; Alexey Nikitin; Olga Brovkina; Dmitry Khodyrev; Alexander Zotov; Nikita Vachrushev; Dmitry Dragunov; Andrey Shim; Mitko Mladenov; Andre Kamkin
Journal:  J Inflamm Res       Date:  2018-01-18

8.  Association between interleukin-6/6R gene polymorphisms and coronary artery disease in Russian population: influence of interleukin-6/6R gene polymorphisms on inflammatory markers.

Authors:  Vadim Mitrokhin; Alexey Nikitin; Olga Brovkina; Dmitry Khodyrev; Alexander Zotov; Nikita Vachrushev; Dmitry Dragunov; Andrey Shim; Mitko Mladenov; Andre Kamkin
Journal:  J Inflamm Res       Date:  2017-10-03

9.  The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis.

Authors:  Nader Salari; Kamran Mansouri; Amin Hosseinian-Far; Hooman Ghasemi; Masoud Mohammadi; Rostam Jalali; Aliakbar Vaisi-Raygani
Journal:  Genes Environ       Date:  2021-01-12

10.  The IL-6 rs1800795 and rs1800796 polymorphisms are associated with coronary artery disease risk.

Authors:  Shuai Lu; Ya Wang; Yijun Wang; Jing Hu; Wu Di; Shuangye Liu; Xiaohui Zeng; Guo Yu; Yan Wang; Zhaohui Wang
Journal:  J Cell Mol Med       Date:  2020-05-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.